ClinicalTrials.gg
RecruitingNCT06057909Updated Feb 3, 2026

A Study of Neurodegeneration and Neuronal Fluctuations in Lewy Body Disease and Alzheimer's Disease

An observational study in Lewy Body Disease, Alzheimer Disease and Healthy, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 50 Years to 95 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-03.

Sponsored by Mayo Clinic · Observational

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
90
Ages
50 Years to 95 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 110 studies in Lewy Body Disease with a site in United States — 32 open to participants now, 39 under way, 1 of them phase 3. Lewy Body Disease · United States.

Planned enrollment
23rd of 31
90 · median 225
Started
2024
with 7 others
Observational
31 of 110
14 open now
Primary completion
2027-06
later than 17 of 38 live
Registered
87th of 110
by date
Lead sponsor
7 of 110
Mayo Clinic

Among the 110 studies in Lewy Body Disease with a site in United States, this one is the 23rd largest by planned enrollment of the 31 observational ones that give a count, is one of 8 that started in 2024, is one of 31 observational ones, reaches primary completion later than 17 of the 38 other live ones, and was the 87th registered.

Lewy Body Disease

240 studies on the registry are indexed under Lewy Body Disease; 89 are open to participants now.

Browse Lewy Body Disease studies →

Open to participants now

32 of the 110 studies in Lewy Body Disease with a site in United States are open now. Recruiting first, the newest first:

26 more — sign in →

All 32 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 64 Lewy Body Disease studies recruiting now, 42 (66%) set no upper age limit and none (0%) stop at 75 or younger; 10 take children under 18; 31 take healthy volunteers.

This study: 50 Years to 95 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies in Lewy Body Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this research study is to investigate how the brain, memory, thinking, and motor behavior change both in individuals with movement and/or cognitive disorders, as well as healthy individuals. Researchers will look at measurements of memory, thinking, brain wave and muscle activity, daily functioning, and brain scans to learn more about brain disorders such as Alzheimer disease and Lewy body disease.

03

Conditions studied

  • Lewy Body Disease
  • Alzheimer Disease
  • Healthy
04

Who can participate

Ages eligible
50 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

This study will include healthy individuals, and patients who have a clinical diagnosis made by a board-certified neurologist of Lewy body disease or Alzheimer disease.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Use English as their primary language.
  • Be willing to undergo health and cognitive assessments, as well as brain MRI and EEG study.
  • Will be encouraged to have an available study partner (also called a "co-participant") who is familiar with the participant's daily functioning.
  • This study will be limited to healthy individuals, and patients who have a clinical diagnosis made by a board-certified neurologist of Lewy body disease or Alzheimer disease.
  • All individuals must be capable of providing and complying with the trial procedures. Realizing the challenge of obtaining informed consent from cognitively impaired individuals, time is specifically scheduled to foster an informative, supportive interview with the participant and caregiver/legal guardian (typically a spouse or child according to Arizona law and IRB guidelines).
  • Ongoing participation will be maintained by strict adherence to inclusion/exclusion criteria, clinical appropriateness (as determined by participant's physician and proxy/family), as well as by expressed wishes of family members/caregivers/proxy discussed at each study visit (as appropriate).
  • All participants will receive copies of the signed ICFs (including signatures of those obtaining consent).
  • All participants have the right to withdraw from the study at any time.

Exclusion criteria

Exclusion Criteria:

  • Individuals will be excluded if they have significant sensory (visual and hearing) deficits or major medical or psychiatric illnesses which would limit participation.
  • Participants will also be excluded if they have history of other major neurologic disorders including stroke, epilepsy, meningitis/encephalitis, metabolic or toxic encephalopathy, penetrating or severe closed head injury, brain tumor/other structural lesion, other primary movement disorders (such as essential tremor, dystonia, chorea, multiple system atrophy, progressive supranuclear palsy, corticobasal syndrome).
  • In addition, as necessitated by the risks of Magnetic Resonance Imaging (MRI), patients who have any type of implanted electrical device (such as a cardiac pacemaker or a neurostimulator including deep brain stimulation), or a certain type of metallic clip in their body (i.e., an aneurysm clip in the brain), are not eligible for participation in the MRI portion of the study. Individuals who experience claustrophobic anxiety will also be excluded from participation.
  • Women who are or might be pregnant and nursing mothers are not eligible.
  • If the subject is a woman of , due to unknown risks to the fetus, they must have a pregnancy test. Individuals who have a history metalworking involving cutting processes such as grinding, filing, shaving, and threading, or history of eye injury involving metal, will also be excluded unless they have had prior documented radiological clearance for MRI.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
90 participants (estimated)
Patient registry
No

Groups and cohorts

  • Lewy Body Disease Group

    Subjects identified by their physician with a diagnosis of Lewy body disease will have a physical and neurological exam, MRI of brain, electroencephalography (EEG), and electromyography (EMG).

    Diagnostic Test: Magnetic Resonance Imaging · Diagnostic Test: Electroencephalography · Diagnostic Test: Electromyography

  • Alzheimer Disease Group

    Subjects identified by their physician with a diagnosis of Alzheimer will have a physical and neurological exam, MRI of brain, electroencephalography (EEG), and electromyography (EMG).

    Diagnostic Test: Magnetic Resonance Imaging · Diagnostic Test: Electroencephalography · Diagnostic Test: Electromyography

  • Healthy Control Group

    Subjects identified as a health individual will have a physical and neurological exam, MRI of brain, electroencephalography (EEG), and electromyography (EMG).

    Diagnostic Test: Magnetic Resonance Imaging · Diagnostic Test: Electroencephalography · Diagnostic Test: Electromyography

Interventions

  • Diagnostic testMagnetic Resonance Imaging

    Test that looks at the structure of the brain.

    Also known as: MRI

  • Diagnostic testElectroencephalography

    Non-invasive technique to measure brain waves

    Also known as: EEG

  • Diagnostic testElectromyography

    Technique to evaluate muscle activity

    Also known as: EMG

06

What researchers measure

Primary outcomes

  1. Diffusion-weighted MRI (dMRI)

    Measures diffusion of water molecules and cellular-level constraints

    Time frame: Baseline

  2. Electroencephalography (EEG)

    Measures brain-wave activity

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Jun 2027, 38 months after the start.

Of 45 observational studies under Lewy Body Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 171. This study's planned 38 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2023
First posted
Sep 28, 2023
StartActual
Apr 5, 2024
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Feb 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06057909
Lead sponsor
Mayo Clinic
Responsible party
Shannon Y. Chiu (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Sep 28, 2023
Start date
Apr 5, 2024
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Feb 3, 2026

Study contacts

Sara Dresler
Contact
dresler.sara@mayo.edu
480-301-6279
Shannon Chiu, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion